| Year |
Citation |
Score |
| 2021 |
DeNicola GM, Shackelford DB. Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer. Cold Spring Harbor Perspectives in Medicine. PMID 34127512 DOI: 10.1101/cshperspect.a037838 |
0.303 |
|
| 2021 |
Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim RJ, Ong SL, Huang ZL, Zhang T, Abascal J, Dumitras C, Jing Z, Park SJ, Krysan K, Shackelford DB, Tran LM, et al. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-deficient Non-Small Cell Lung Cancer. Cancer Research. PMID 33853830 DOI: 10.1158/0008-5472.CAN-20-3564 |
0.346 |
|
| 2020 |
Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, et al. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity. Cancer Discovery. PMID 33318037 DOI: 10.1158/2159-8290.CD-20-0873 |
0.351 |
|
| 2020 |
Riess JW, Frankel P, Shackelford D, Dunphy M, Badawi RD, Nardo L, Cherry SR, Lanza I, Reid J, Gonsalves WI, Kunos C, Gandara DR, Lara PN, Newman E, Paik PK. Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. Clinical Lung Cancer. PMID 33229301 DOI: 10.1016/j.cllc.2020.10.006 |
0.323 |
|
| 2018 |
Eichner LJ, Brun SN, Herzig S, Young NP, Curtis SD, Shackelford DB, Shokhirev MN, Leblanc M, Vera LI, Hutchins A, Ross DS, Shaw RJ, Svensson RU. Genetic Analysis Reveals AMPK Is Required to Support Tumor Growth in Murine Kras-Dependent Lung Cancer Models. Cell Metabolism. PMID 30415923 DOI: 10.1016/J.Cmet.2018.10.005 |
0.304 |
|
| 2018 |
Momcilovic M, Shackelford DB. Dual targeting of EGFR and glutaminase in lung cancer. Molecular & Cellular Oncology. 5: e1297883. PMID 30250881 DOI: 10.1080/23723556.2017.1297883 |
0.351 |
|
| 2018 |
Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, Graeber TG, Parlati F, Demo S, Li R, Walser TC, Gricowski M, Shuman R, Ibarra J, Fridman D, ... ... Shackelford DB, et al. The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. Cancer Cell. 33: 905-921.e5. PMID 29763624 DOI: 10.1016/J.Ccell.2018.04.002 |
0.334 |
|
| 2017 |
Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, ... ... Shackelford DB, et al. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Reports. 18: 601-610. PMID 28099841 DOI: 10.1016/J.Celrep.2016.12.061 |
0.317 |
|
| 2016 |
Jiang W, Finniss S, Cazacu S, Xiang C, Brodie Z, Mikkelsen T, Poisson L, Shackelford DB, Brodie C. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. Oncotarget. PMID 27486821 DOI: 10.18632/Oncotarget.10919 |
0.411 |
|
| 2015 |
Momcilovic M, McMickle R, Abt E, Seki A, Simko SA, Magyar C, Stout DB, Fishbein MC, Walser TC, Dubinett SM, Shackelford DB. Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers. Cancer Research. 75: 4910-22. PMID 26574479 DOI: 10.1158/0008-5472.Can-15-0797 |
0.336 |
|
| 2015 |
Momcilovic M, Shackelford DB. Targeting LKB1 in cancer-exposing and exploiting vulnerabilities British Journal of Cancer. 113: 574-584. PMID 26196184 DOI: 10.1038/bjc.2015.261 |
0.381 |
|
| 2014 |
Faubert B, Vincent EE, Griss T, Samborska B, Izreig S, Svensson RU, Mamer OA, Avizonis D, Shackelford DB, Shaw RJ, Jones RG. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proceedings of the National Academy of Sciences of the United States of America. 111: 2554-9. PMID 24550282 DOI: 10.1073/Pnas.1312570111 |
0.308 |
|
| 2013 |
Wei W, Shi Q, Remacle F, Qin L, Shackelford DB, Shin YS, Mischel PS, Levine RD, Heath JR. Hypoxia induces a phase transition within a kinase signaling network in cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 110: E1352-60. PMID 23530221 DOI: 10.1073/Pnas.1303060110 |
0.317 |
|
| 2013 |
Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS, Shaw RJ. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 23: 143-58. PMID 23352126 DOI: 10.1016/J.Ccr.2012.12.008 |
0.381 |
|
| 2009 |
Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL, Vera DR, Shaw RJ. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proceedings of the National Academy of Sciences of the United States of America. 106: 11137-42. PMID 19541609 DOI: 10.1073/Pnas.0900465106 |
0.41 |
|
| 2007 |
Shackelford D, Wang Y, Waxman S, Ren R. Reactive Oxygen Species Target the Degradation of the EVI1 Oncoprotein. Blood. 110: 651-651. DOI: 10.1182/Blood.V110.11.651.651 |
0.6 |
|
| 2006 |
Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Research. 66: 11360-9. PMID 17145882 DOI: 10.1158/0008-5472.Can-06-1774 |
0.464 |
|
| 2005 |
Shackelford D, Kenific C, Waxman S, Ren R. Arsenic Trioxide Targets the MDS1 and EVI1- Containing Oncoproteins for Degradation by Proteasome Dependent and Independent Mechanisms. Blood. 106: 1612-1612. DOI: 10.1182/Blood.V106.11.1612.1612 |
0.624 |
|
| 2004 |
Shackelford D, Waxman S, Ren R. Arsenic Trioxide (ATO) Downregulates the Expression of the AML1/MDS1/EVI-1 (AME) Oncoprotein and Induces Differentiation and Apoptosis in AME-Leukemic Cells. Blood. 104: 4466-4466. DOI: 10.1182/Blood.V104.11.4466.4466 |
0.588 |
|
| Show low-probability matches. |